Search Results
May 13, 2026, 06:30 ET Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
million in gross proceeds, led by existing investor BVF Partners L.P. with participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other
More news about: Immunic, Inc.
Feb 26, 2026, 06:30 ET Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
million in gross proceeds, led by existing investor BVF Partners L.P. with participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other
More news about: Immunic, Inc.
Feb 17, 2026, 16:05 ET Immunic Announces Closing of Oversubscribed Private Placement Financing
financing.The financing was led by BVF Partners L.P. and included participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other
More news about: Immunic, Inc.
Feb 13, 2026, 06:30 ET Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
financing was led by existing investor BVF Partners L.P. and included participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other
More news about: Immunic, Inc.
Oct 20, 2025, 11:00 ET Resistance to Epilepsy Treatments May Wane Over Time
Capsida Biotherapeutics, Cerebral Therapeutics, Cerecin Neurosciences, Cerevel Therapeutics, Ceribell, Cognizance Biomarkers, Cowen and Co., Crossject, EcoR1 Capital, Eisai Co., Encoded Therapeutics, Engrail, EpiMinder, Epitel, Équilibre BioPharmaceuticals Corp., Genentech, GRIN Therapeutics, Harmony Biosciences/Epygenix
More news about: NYU Grossman School of Medicine and NYU Langone Health